Trade Galapagos NV - GLPG CFD

Add to favourite

21.95

0.23%

0.15

Low: 21.7

High: 21.9

Market Trading Hours* (UTC) Open now
Closes on Friday at 15:30

Mon - Fri: 07:00 - 15:30

Summary
Historical Data

Trading сonditions

Spread

0.15

Long position overnight fee

-0.017952%

Short position overnight fee

-0.004271%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

EUR

Margin

5.00%

Stock exchange

Netherlands

Commission on trade

Key Stats

Prev. Close	21.85
Open	21.75
1-Year Change	-25.51%
Day's Range	21.7 - 21.9

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 3, 2025	21.85	0.10	0.46%	21.75	22.70	21.75
Apr 2, 2025	23.05	0.30	1.32%	22.75	23.05	22.45
Apr 1, 2025	23.25	0.50	2.20%	22.75	23.55	22.75
Mar 31, 2025	23.15	-0.05	-0.22%	23.20	23.20	22.65
Mar 28, 2025	23.45	0.00	0.00%	23.45	23.70	23.35
Mar 27, 2025	23.55	0.25	1.07%	23.30	23.65	23.30
Mar 26, 2025	23.65	-0.20	-0.84%	23.85	23.85	23.55
Mar 25, 2025	23.95	0.25	1.05%	23.70	24.35	23.70
Mar 24, 2025	23.95	0.25	1.05%	23.70	24.10	23.55
Mar 21, 2025	24.00	0.65	2.78%	23.35	24.00	23.30
Mar 20, 2025	23.80	-0.05	-0.21%	23.85	24.10	23.70
Mar 19, 2025	23.85	0.25	1.06%	23.60	23.90	23.50
Mar 18, 2025	23.65	-0.05	-0.21%	23.70	24.05	23.55
Mar 17, 2025	23.85	0.00	0.00%	23.85	24.10	23.65
Mar 14, 2025	23.90	0.15	0.63%	23.75	24.35	23.75
Mar 13, 2025	23.65	-0.60	-2.47%	24.25	24.35	23.60
Mar 12, 2025	24.30	0.70	2.97%	23.60	24.75	23.60
Mar 11, 2025	23.45	0.05	0.21%	23.40	24.00	23.25
Mar 10, 2025	23.85	-0.40	-1.65%	24.25	24.25	23.70
Mar 7, 2025	24.40	0.15	0.62%	24.25	24.60	23.85

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Galapagos NV Company profile

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Galapagos NV revenues increased 2% to EUR538.6M. Net loss before extraordinary items decreased 60% to EUR125.4M. Revenues reflect Total net revenues increase of 1% to EUR484.8M, Other operating income increase of 3% to EUR53.7M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR4.78 to -EUR1.92.